… Glyceryl monooleate (GMO) as co-formers for creating Cubosomes and SAIB-based
nanodispersions of Rivaroxaban … improved drug release compared to XARELTO®. L4 displayed …

… We conducted weight variation, hardness, and friability tests on RXB and Xarelto tablets to
… that the Xarelto tablets had a weight variation of (1.59% ±0.18), while the L4 tablets had a …

… immediate-release tablets, Xarelto tablets, and RXN LSC-based tablets were performed …
Neat RXN/immediate-release tablets/Xarelto tablets/RXN LSC-based tablets (containing 10 …

… A novel oral anticoagulant drug named Rivaroxaban ‘RX’ will be studied in this research …
We evaluated the effects of drug concentration, poloxamer to glyceryl monooleate ratio, and …

… use of Sucrose acetate isobutyrate (SAIB) and Glyceryl monooleate (GMO) as co-formers
for creating Cubosomes and SAIB-based nanodispersions of Rivaroxaban (RXB). The process …

… as Apixaban and Rivaroxaban have gained significant attention for their effectiveness in
preventing and treating thromboembolic disorders. Both Apixaban and Rivaroxaban have been …

Apixaban (APX) is a potent oral anticoagulant drug that directly inhibit coagulation factor Xa
for prevention of venous thromboembolism (VTE) following total hip or knee replacement …

… Meanwhile, biorelevant media such as Fed State Simulated Intestinal Fluid (FeSSIF-V2)
includes fatty acid (ie, oleic acid) and monoglyceride (eg, glycerol monooleate), although is not …

… For direct Fxa inhibitors, rivaroxaban and apixaban were widely prescribed for patients with
… delivery of enoxaparin, which used chitosan graft glyceryl monooleate (CS–GO), was also …

Lipid-based formulations have emerged as prospective dosage forms for extracting the
therapeutic effects of existing lipophilic compounds and novel chemical entities more efficiently. …